XML 57 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 15, 2017
USD ($)
Dec. 24, 2018
Sep. 25, 2017
USD ($)
May 26, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 31, 2015
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2017
USD ($)
Jan. 31, 2022
shares
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Collaborative Agreements (Details) [Line Items]                            
Milestone payments royalty percentage                 12.00% 12.00%        
Co-Dev agreement, description   the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                        
Shares issued (in Shares) | shares                       1,306,007    
BHK Co-Development Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Milestone payment           $ 31,649,000 $ 10,000,000              
Description of payment settlement             ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment     ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment     ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment              
Upfront cash payment               $ 1,000,000            
Percentage of payments under co-development agreement               10.00%            
Common stock newly issued, value         $ 1,000,000     $ 10,000,000            
Collaborative agreements, description               In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.        
BHK Co-Development Agreement [Member] | BioLite Taiwan [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Description of payment settlement             ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment     ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment     ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment              
Co-Dev Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Percentage of payments under co-development agreement       50.00%                    
Company cash payments $ 3,000,000                          
Addition cash payment       $ 3,000,000                    
Additional paid-in capital                     $ 3,000,000      
Amount received                     450,000      
Collaborative Arrangement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Percentage of payments under co-development agreement                 50.00% 50.00%        
Common stock newly issued, value                 $ 3,000,000 $ 3,000,000        
Company cash payments                 $ 3,000,000 $ 3,000,000        
Licensing rights     $ 3,000,000                      
Research and development expense                     $ 3,000,000      
BioFirst Stock Purchase Agreement [Member]                            
Collaborative Agreements (Details) [Line Items]                            
Amount received                         $ 2,902,911 $ 3,000,000
Shares issued (in Shares) | shares                         414,702 428,571